{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:11:49Z","timestamp":1773295909202,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Redes Telem\u00e1ticas de Investigaci\u00f3n Cooperativa en Salud","award":["Red de SIDA RD12\/0017\/0029"],"award-info":[{"award-number":["Red de SIDA RD12\/0017\/0029"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["PI12\/02283"],"award-info":[{"award-number":["PI12\/02283"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["CP08\/00172"],"award-info":[{"award-number":["CP08\/00172"]}]},{"name":"Fondo de Investigaciones Sanitarias","award":["CPII014\/00025"],"award-info":[{"award-number":["CPII014\/00025"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.antiviral.2015.06.018","type":"journal-article","created":{"date-parts":[[2015,6,27]],"date-time":"2015-06-27T20:48:17Z","timestamp":1435438097000},"page":"94-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in na\u00efve HIV-infected patients"],"prefix":"10.1016","volume":"121","author":[{"given":"Miguel","family":"Genebat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca S.","family":"de Pablo-Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildefonso","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel E.","family":"Jim\u00e9nez-Mej\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onofre","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda M.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Raffi-El-Idrissi Benhia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Antonia","family":"Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.06.018_b0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use correlates with disease progression in HIV-1-infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.06.018_b0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.018_b0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkp293","article-title":"Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients","volume":"64","author":"Genebat","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.06.018_b0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.antiviral.2010.11.015","article-title":"Discordance rates between Trofile test and short-term virological response to maraviroc","volume":"89","author":"Genebat","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.018_b0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.antiviral.2012.06.007","article-title":"Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment","volume":"95","author":"Genebat","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.018_b0030","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/AAC.05857-11","article-title":"Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods","volume":"56","author":"Gonz\u00e1lez-Serna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.018_b0035","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/AAC.00507-12","article-title":"HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients","volume":"56","author":"Gonz\u00e1lez-Serna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.018_b0040","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/jac\/dku059","article-title":"Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients","volume":"69","author":"Hern\u00e1ndez-Novoa","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.06.018_b0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","article-title":"Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study","volume":"62","author":"Mills","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2015.06.018_b0050","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1128\/AAC.00148-10","article-title":"Evaluation of the genotypic prediction of HIV-1 coreceptor usage versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS Genotropism study","volume":"338","author":"Recordon-Pinson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.018_b0055","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/AAC.00753-11","article-title":"Virological response after short-term CCR5-antagonists exposure in HIV-infected patients: frequency of subjects with virological response and associated factors","volume":"55","author":"Ruiz-Mateos","year":"2011","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T04:57:29Z","timestamp":1537505849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":11,"alternative-id":["S0166354215001497"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.018","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in na\u00efve HIV-infected patients","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}